GENE ONLINE|News &
Opinion
Blog

Feature
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
For the very first time in history, Medicare will be able to negotiate lower prescription drug prices since the passage of the Inflation Reduction Act by Congress last August and its signing by President Joe Biden.

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), issued initial guidance on March 15 that details the requirements and parameters associated with crucial elements of the new Medicare Drug Price Negotiation Program and includes requests for public comment. The new negotiated prices will apply for the first time in 2026.

According to Xavier Becerra, Secretary of HHS, “Through the Medicare Drug Price Negotiation Program, we will make sure seniors get a fair price on Medicare’s costliest prescription drugs, promote competition in the market, and ensure Medicare is strong for beneficiaries today and into the future.”

2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
Special
Comparing ESG Regulations in the U.S., the U.K., and the EU
Environmental, social, and corporate governance (ESG) is a rapidly evolving framework designed to hold companies accountable for their actions and increase understanding of how an organization or company manages its risks around these issues. In a perfect world, ESG knowledge would increase investor knowledge, maximizing stakeholder well-being.

Still, with so many confounding factors surrounding sustainability, human rights, labor conditions, and diversity in the workplace, standardizing ESG reporting is difficult, to say the least, in a corporate world filled with different industries with different objectives. Several countries and regions worldwide have worked and continue to work to standardize ESG reporting methods and requirements to give investors the best opportunity to get a clear picture of where they are putting their money and provide more robust frameworks for companies’ futures. 

The U.S., the U.K., and the EU are huge markets that ESG significantly impact. In the ever-evolving landscape, though, the three areas hold different ESG requirements and are developing new, better ways for companies to report ESG considerations. 

2023-03-21
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
Following in the footsteps of two major competitors in the insulin market, Eli Lilly and Novo Nordisk, Sanofi earlier issued a press release announcing a …

Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors Read More »

2023-03-19
Novo Nordisk Announces Major Insulin Price Cut by Up to 75%, Following in the Footsteps of Eli Lilly
Danish drugmaker Novo Nordisk recently announced a reduction in the list price of several insulin drugs in the United States by up to 75%, making it the latest major pharmaceutical company to slash the insulin price amid pressure to curb the treatment costs for diabetics in the country. 

The price change, which will take effect on January 1, 2024, follows a path set earlier this month by Eli Lilly, one of the major rivals of Novo Nordisk in the insulin market of the United States. It involves the company’s pre-filled pens (FlexPen) as well as vials of long- and short-acting insulins, including Levemir, Novolin, NovoLog and NovoLog Mix70/30. 

The list prices for Levemir and Novolin vials and FlexPens will be reduced by 65%, while NovoLog and NovoLog Mix 70/30 will become 75% cheaper. The list prices of unbranded insulin products will also be reduced to match lowered prices of respective branded insulin products.

2023-03-15
LATEST
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Deals
In-Home Kidney Disease Management Company, Monogram, Raises $375 Million
2023-01-13
Belharra Therapeutics Exits Stealth With $130 Million And A Genentech Deal
2023-01-05
Zenas Picks Up $118 Million To Advance Phase 3 For Autoimmune Candidate
2022-11-10
Soon-To-Be J&J Spinoff, Kenvue Files for $100 Million IPO
2023-01-06
Alkermes to Break Oncology Sector into Independent Company
2022-11-03
Shenzhen Joincare Plots $300 Million IPO On Swiss Exchange
2022-06-20
Pfizer Acquires Seagen for $43 Billion to Capture Leading Position in Oncology
2023-03-14
BioTouch Buys Ireland’s Titan Solutions To Expand International Outreach
2023-03-03
Kinnate Buys Back $24 Million Worth Of Shares From China Venture Kinnjiu
2023-02-22
Ranking & Reports
Investigate the Current Status of Rivaroxaban Generic Drug Application in China
2023-03-01
Patent Landscape Analysis of Gene Therapy
2023-02-08
Will Breakthrough Therapy Lead the Way? An Overview of the Approved Gene and Cell Therapies for 2022
2023-01-13
Categories
Industrializing iPSC and Harnessing its Medical Applications – An Interview with Dr. Hong-Lin Su
2023-03-06
Transforming Southern California Biotech Landscape: An Interview With SoCalBio CEO Ahmed Enany
2022-10-18
Cell Therapy as a Pillar of Future Therapeutics, an Interview with Alex Huang, Vice President and Head of Cell Therapy at BeiGene
2022-10-05
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Astellas Clears Primary Endpoints In Prostate Cancer And Menopause Trials
2023-03-14
Global Head of Research of Kite Pharma Unveiled the Key Elements to Success in Adoptive Cell Therapy
2023-03-07
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Investigate the Current Status of Rivaroxaban Generic Drug Application in China
2023-03-01
Kinnate Buys Back $24 Million Worth Of Shares From China Venture Kinnjiu
2023-02-22
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Biodegradable Skin Staple! KMU Earned Major Recognition in the Annual Main Event of Plastic Surgery
2023-02-09
In-Home Kidney Disease Management Company, Monogram, Raises $375 Million
2023-01-13
Belharra Therapeutics Exits Stealth With $130 Million And A Genentech Deal
2023-01-05
Will Biden’s Biomanufacturing Initiative Kill Korean Partnership?
2022-10-12
Government Agencies Spring into Action After Biomanufacturing Executive Order
2022-09-14
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
Merck Strikes $50 Million Deal with ModeX For Rights to EBV Vaccine
2023-03-08
Lineage Books Eterna For Allogeneic Cell Therapies In License Option Deal
2023-02-23
First-Ever Insect Brain Neuron Map Completed
2023-03-21
The World’s First mRNA Vaccine to Fight Against Antibiotic-Resistant Bacteria
2023-03-14
Fifth HIV Patient Cured After Stem Cell Transplant in Germany
2023-03-01
Biodegradable Skin Staple! KMU Earned Major Recognition in the Annual Main Event of Plastic Surgery
2023-02-09
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Scroll to Top